Charles Schwab Investment Management Inc. Has $757,000 Holdings in PetMed Express, Inc. (NASDAQ:PETS)

Charles Schwab Investment Management Inc. reduced its stake in PetMed Express, Inc. (NASDAQ:PETS) by 49.3% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 205,635 shares of the company’s stock after selling 200,150 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in PetMed Express were worth $757,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in PETS. Sei Investments Co. lifted its position in shares of PetMed Express by 8.3% during the 2nd quarter. Sei Investments Co. now owns 44,220 shares of the company’s stock valued at $179,000 after acquiring an additional 3,400 shares during the period. Point72 DIFC Ltd acquired a new position in PetMed Express in the second quarter valued at about $34,000. Marshall Wace LLP bought a new stake in PetMed Express during the second quarter worth about $46,000. SG Americas Securities LLC acquired a new stake in PetMed Express during the second quarter worth about $46,000. Finally, Legacy Advisors LLC bought a new position in PetMed Express in the 2nd quarter valued at about $96,000. Institutional investors and hedge funds own 73.33% of the company’s stock.

PetMed Express Stock Down 5.4 %

Shares of PETS stock opened at $5.28 on Thursday. The business has a fifty day simple moving average of $4.71 and a 200 day simple moving average of $4.07. The company has a market cap of $109.08 million, a P/E ratio of -88.00 and a beta of 0.71. PetMed Express, Inc. has a twelve month low of $2.90 and a twelve month high of $7.79.

PetMed Express (NASDAQ:PETS) last posted its earnings results on Wednesday, November 6th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.17. The firm had revenue of $59.57 million during the quarter, compared to analysts’ expectations of $66.02 million. PetMed Express had a negative net margin of 0.37% and a negative return on equity of 1.00%. As a group, equities research analysts anticipate that PetMed Express, Inc. will post 0.24 earnings per share for the current fiscal year.

Insider Buying and Selling at PetMed Express

In other news, Director Leslie C.G. Campbell purchased 15,000 shares of PetMed Express stock in a transaction dated Wednesday, December 4th. The shares were bought at an average cost of $5.38 per share, for a total transaction of $80,700.00. Following the completion of the acquisition, the director now owns 70,000 shares in the company, valued at approximately $376,600. This trade represents a 27.27 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.10% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded shares of PetMed Express from a “hold” rating to a “buy” rating in a research report on Tuesday, November 12th.

About PetMed Express

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.